• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Volitinib

Volitinib

Product ID V574451
Cas No. 1313725-88-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $106.40 In stock
5 mg $170.40 In stock
25 mg $476.90 In stock
100 mg $1,342.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Volitinib is an inhibitor of c-Met. It shows antitumor potential in models of gastric cancer. It is being investigated as a treatment for papillary renal cell carcinoma, where it has demonstrated an acceptable tolerability profile.

Product Info

Cas No.

1313725-88-0

Purity

≥98%

Formula

C17H15N9

Formula Wt.

345.37

Chemical Name

Volitinib

IUPAC Name

1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine

Synonym

Savolitinib, HMPL 504, HMPL0-504, HMPL504, AZD-6094, AZD 6094, AZD6094

Solubility

Insoluble in water. Solubility in DMSO - ~15 mg/mL.

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

V574451 MSDS PDF

Info Sheet

V574451 Info Sheet PDF

References

Gavine P., Ren Y., et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 9(1):323-33 (2015). PMID: 25248999.

Gan H., Millward M., et al. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and Anti-Tumor Activity. Clin Cancer Res. 2019. PMID: 30952639.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B1652

    Benzo[a]pyrene

    Polycyclic aromatic hydrocarbon (PAH) found in ...

    ≥98%
  • E5576

    Entecavir

    Nucleoside (deoxyguanosine) analog; DNA chain t...

    ≥97%
  • F8151

    Fumonisin B3

    Mycotoxin produced by Fusarium fungi that infec...

    ≥98%
  • G0668

    GBR 12935 Dihydrochloride

    DAT inhibitor.

    ≥98%
  • D760022

    DT-2216

    BCL-XL specific degrader

    ≥98%
  • A044178

    Abemaciclib mesylate

    CDK inhibitor.

    ≥98%
  • A001001

    A 83-01

    TGFbeta receptor inhibitor

    ≥98%
  • T3040

    Thienylpentyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥98%
  • V3252

    Vinorelbine Ditartrate

    Semi-synthetic vinca alkaloid from Catharanthus...

    ≥98%
  • L589921

    Loxapine Succinate

    D2 and D4 dopamine receptor inhibitor.

    ≥99%
  • V1769

    Verapamil Hydrochloride

    L-type Ca2+ channel blocker.

    ≥98%
  • H1992

    Hexaconazole

    Triazole; demethylation inhibitor.

    ≥95%
  • V9201

    VX-11e

    ERK2 inhibitor, potential AurKA, GSK3, CDK2, FL...

    ≥98%
  • T5720

    Tofacitinib Citrate

    JAK1/2/3 inhibitor.

    ≥99%
  • S6233

    Spiramycin Hexanedioate

    Macrolide; protein synthesis inhibitor.

    ≥90%
  • S4932

    SMI-4a

    Thiazolidine; Pim kinase inhibitor.

    ≥99%
  • C8017

    Cuelure

    Hormonal attractant for male Bactrocera flies.<...

    ≥97%
  • C000078

    C-178

    STING inhibitor

    ≥99%
  • A7208

    Ascomycin

    FK506 analog; calcineurin inhibitor.

    ≥98%
  • A7668

    Atracurium Besylate

    Non-depolarizing NMJ blocker; AChR antagonist.<...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only